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Open access under CC BCarbohydrate responsive element-binding protein (ChREBP) is a transcription factor whose expression
and activity are increased in pancreatic b-cells maintained at elevated glucose concentrations. We show
here that ChREBP inactivation in clonal pancreatic MIN6 b-cells results in an increase in Pdx-1 expression
at low glucose and to a small, but signiﬁcant, increase in Ins2, GcK and MafA gene expression at high glu-
cose concentrations. Conversely, adenovirus-mediated over-expression of ChREBP in mouse pancreatic
islets results in decreases in Pdx-1, MafA, Ins1, Ins2 and GcK mRNA levels. These data suggest that strat-
egies to reduce ChREBP activity might protect against b-cell dysfunction in type 2 diabetes.
 2010 Elsevier Inc. Open access under CC BY license.1. Introduction L-type pyruvate kinase (L-PK) [9,10], and the proapoptotic genePancreatic b-cell glucolipotoxicity [1] is considered to play a
signiﬁcant role in the pathogenesis of type 2 diabetes. Carbohy-
drate responsive element-binding protein (ChREBP) is a member
of the basic helix–loop–helix family of transcription factors and
transactivates glucose-responsive genes by binding to DNA as a
heterodimer with Max-like protein X1 at a well-deﬁned carbohy-
drate-responsive element (ChoRE) [2–5]. In the liver, ChREBP is
responsible for converting excess carbohydrate to fatty acids for
long-term storage [6]. Mice deleted for both alleles of ChREBP dis-
play diminished rates of hepatic glycolysis and lipogenesis result-
ing in high liver glycogen content, low plasma free fatty acid levels
and reduced adipose tissue mass [7]. Loss of ChREBP in leptin-null
ob/ob mice protects against obesity [7,8].
We, and others, have previously shown that, in pancreatic
b-cells, ChREBP is activated by high glucose and is responsible for
the induction of the lipogenic genes fatty acid synthase (FAS) anduclear translocator; ChREBP,
hIP, chromatin immunopre-
FAS, fatty acid synthase; GcK,
xia inducible factor; L-PK, L-
m homeobox-1; siRNA, small
-element-binding protein-1c;
iology, Department of Medi-
ng Building, Imperial College
351.
.
Y license.Txnip [11,12]. ChREBP also represses aryl hydrocarbon receptor nu-
clear translocator/hypoxia inducible factor 1-b (ARNT/HIF1-b) [13]
shown recently to be diminished in islets [14] and liver [15] of type
2 diabetic humans, and necessary for normal b-cell function and
repression of hepatic gluconeogenesis. We sought here to investi-
gate the effects of ChREBP silencing and over-expression on other
key glucose-responsive genes in pancreatic islet b-cells, namely
pancreatic and duodenal homeobox-1 (Pdx-1), MafA, glucokinase
(GcK) and insulin, all critical for normal pancreatic b-cell function.
2. Materials and methods
2.1. Materials
Primers for siRNA construction and PCR were from MWG Bio-
tech (Milton Keynes, UK). Antibodies were described in [9]. Other
reagents were from Sigma or Invitrogen.
2.2. Plasmids, adenoviruses and siRNA
pChREBP and ChREBP siRNA have been described in [9]. Adeno-
virus encoding for ChREBP has been described in [13]. Plasmids
and adenoviruses encoding GFP-null and constitutively active
and dominant negative forms of SREBP-1c were described in
[16]. pPdx1.LucFF, encoding the 50 ﬂanking region of the mouse
pancreatic duodenum homeobox-1 (Pdx-1) gene (2715 to 0 bp),
was generated by PCR from MIN6 cell genomic DNA with the fol-
lowing primers: forward, 50-ATAT GG TACC CTC CAG TAT CAG
Table 1
Primers used for real-time RT-PCR.
mRNA Forward primer 50–30 Reverse primer 50–30
MafA CACCACGTGCGCTTGG CAGAAAGAAGTCGGGTG
Pdx-1 TGGAGCTGGCAGTGATGTTGA TCAGAGGCAGATCTGGCCAT
Ins1 GAAGCGTGGCATTGTGGAT TGGGCCTTAGTTGCAGTAGTTCT
Ins2 AGCCCTAAGTGATCCGCTACAA CATGTTGAAACAATAACCTGGAAGA
GcK GCTTTTGAGACCCGTTTTGTG GCCTTCGGTCCCCAGAGT
Cyclophilin TATCTGCACTGCCAAGACTGA CCACAATGCTCATGCCTTCTTTCA
Table 2
Effects of glucose and ChREBP silencing on mRNA levels in MIN6 cells.
[Glucose] Scrambled siRNA ChREBP siRNA
3 mM 30 mM 3mM 30 mM
MafA 0.0294 ± 0.0002 0.0332 ± 0.0002 0.0297 ± 0.0002 0.0395 ± 0.0002,–
GcK 0.397 ± 0.0002 0.927 ± 0.0006 0.386 ± 0.0002 1.14 ± 0.0001,–
Ins2 3.52 ± 0.004 9.79 ± 0.004 3.48 ± 0.0007– 10.2 ± 0.004,–
Culture conditions, total RNA preparation and real-time RT-PCR conditions were as described in Fig. 3. Data are means ± SEM from three independent experiments performed
in triplicates, and normalized to cyclophilin mRNA levels. ,  indicate p < 0.05, 0.0001 for the effect of glucose and – indicates p < 0.05, for the effect of ChREBP siRNA.
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CCC CAG ATC GCT TTG A-30 (SacI site underlined) and subcloned
into pGL3 basic (Promega). Two point mutations [106C > A;
102T > G] in the Pdx-1 promoter were introduced using Quick-
change™ (Stratagene) with the following sense primer: 50-ATG
GCT CCA GGG TAA ACA ACG GGG GGT GCC CCA GAG CCT ATG-30.
2.3. MIN6 cell culture and islet of Langerhans isolation
MIN6 cells were cultured as in [9]. Mouse islets of Langerhans
were isolated and cultured as in [13].
2.4. Single cell reporter gene assay
Intranuclear microinjection of plasmids, antibodies and siRNAs
in MIN6 cells were performed at plasmid concentrations of 0.1
(pPdx1.LucFF), and 0.05 (pChREBP, pSREBP-1c, pCMV-RL) mg ml1,
and antibody against ChREBP and SREBP at 1 mg ml1, before
imaging as described in [9].
2.5. Real-time RT-PCR
Total mRNA isolation, cDNA generation and real-time quantita-
tive PCR were performed with primers listed in Table 1, as in [13]
and according to the manufacturer’s instructions. Levels of mRNA
encoding the indicated genes were normalized compared with
cyclophilin mRNA and expressed as the fold change over control
(null, 3 mM glucose) and presented as the means ± SEM.
2.6. Chromatin immunoprecipitation assay
Chromatin immunoprecipitation was performed essentially as
described in [9,13].
2.7. Statistical analysis
Data are given as means ± SEM. Comparisons between means
were performed by unpaired two-tailed Student’s t-test with Bon-
ferroni correction as appropriate, using Microsoft Excel.
3. Results
3.1. ChREBP silencing enhances glucose-responsive gene expression in
MIN6 pancreatic b-cells
We have previously shown that ChREBP silencing in pancreatic
murine insulinoma MIN6 b-cells improves glucose-stimulatedinsulin secretion, possibly through a decrease in total triglyceride
content [9]. Here, we examined the impact of ChREBP silencing
by RNA interference on other glucose-responsive genes in MIN6
b-cells. ChREBP knockdown increased the levels of mRNA encoding
MafA, GcK and Ins2 at high (30 mM) glucose concentrations,
whereas ChREBP silencing increased the expression of the Pdx-1
gene at low (3 mM) glucose concentrations (Table 2 and Fig. 1A).
Correspondingly, we observed a similar increase in Pdx-1 promoter
activity at low glucose after ChREBP inhibition by microinjection of
a speciﬁc anti-ChREBP antibody (Fig. 1C), while introduction of a
ChREBP expression vector by microinjection suppressed the activ-
ity of Pdx-1 promoter at high glucose (Fig. 1E). By contrast, SREBP1-
c inactivation or over-expression was without effect on Pdx-1 pro-
moter activity or mRNA levels (Fig. 1B, D and F).3.2. ChREBP modulation of Pdx-1 gene expression might be indirect
We next sought to identify the region on the Pdx-1 promoter
responsive to ChREBP repression. No consensus ChoRE exists on
the Pdx-1 promoter, but a proximal E-box, located at 105 bp
(Fig. 2A) is highly conserved between species, is protected in
DNAse footprints, and has been proposed to confer b-cell speciﬁc-
ity to the Pdx-1 promoter [17]. Up to now, it has been thought that
this site predominantly binds USF, since mutations abolishing the
binding of the latter factor impair the activity of the Pdx-1 pro-
moter, whereas over-expression of a dominant-negative USF2
reduces both Pdx-1 promoter activity as well as Pdx-1 mRNA and
protein levels [17,18]. Indeed, mutation of this site abolished both
the glucose response and the repressive effect of ChREBP of the
Pdx-1 reporter construct (Fig. 2B). However, neither ChREBP,
USF2 nor SREBP-1c binding could be detected to the proximal
(260 to +1) region of the promoter by chromatin immunoprecip-
itation (Fig. 2C). By contrast, and as previously reported [9], ChRE-
BP binding was readily detectable on the proximal L-PK promoter
at elevated glucose concentrations (Fig. 2C, bottom panel). We also
used this approach to screen a further 11 E-boxes lying in the Pdx-
1 promoter region between 2.7 and 0.26 kb (Fig. 3) but could
not reveal evidence for ChREBP (not shown).
3.3. Adenovirus-mediated over-expression of ChREBP inhibits
glucose-responsive gene expression in isolated mouse islets of
Langerhans
We next examined the effects of ChREBP over-expression on
the levels of mRNAs encoding the above glucose-responsive
Fig. 1. ChREBP is a repressor of Pdx-1 gene expression in MIN6 cells. (A,B) MIN6 cells were cultured for 48 h in the presence of scrambled or ChREBP siRNA (A), or in the
presence of null or SREBP-DN adenoviruses (B), then overnight in 3 mM glucose and ﬁnally for 6 h in 3 or 30 mM glucose prior to cell lysis, total RNA extraction and real-time
quantitative RT-PCR (see Section 2). (C,D) Pdx-1 promoter activity was monitored via nuclear and cytoplasmic microinjection of Pdx-1 promoter–reporter system and anti-
ChREBP (C) or anti-SREBP (D) antibodies (1 mg ml1), or control IgG as indicated, before culture at the indicated glucose concentrations for 6 h and luciferase imaging as
described in Section 2. (E,F) Pdx-1 promoter activity was monitored as above but after co-microinjection of pChREBP (E) or SREBP-CA (F) plasmids. Data are the means ± SEM
of three separate experiments.
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duced either with a null adenovirus encoding GFP only or with
an adenovirus encoding full length wild-type ChREBP [13]. ChRE-
BP over-expression resulted in a decrease in the levels of the
mRNA encoding Pdx-1, MafA and GcK at both low and high glu-
cose concentrations, and Ins1 and Ins2 at low glucose concentra-
tions only (Fig. 4).4. Discussion
4.1. Deﬁning a role for ChREBP in glucose-induced pancreatic b-cell
dysfunction and diabetes
ChREBP is emerging as an important transcription factor in
the pathogenesis of obesity and diabetes and their complications.
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Fig. 2. Chromatin immunoprecipitation fails to reveal direct ChREBP binding at the proximal Pdx-1 promoter. (A) DNA sequence of the proximal mouse Pdx-1 promoter
showing relevant E-box motifs. Arrows represent the primers used for ChIP assay in (C). (B) Cells were microinjected with either wild-type or mutated pPdx-1.LucFF plus
pCMV.RL, plus either empty pcDNA3 or pChREBP as indicated, and incubated and imaged as in Fig. 1. (C) MIN6 cells were cultured in medium containing 3 mM glucose for
16 h prior to stimulation with media containing 3 or 30 mM glucose for 24 h prior to chromatin immunoprecipitation using the antibodies and primers to amplify either Pdx-
1 or L-PK promoter as indicated alongside the ﬁgure. Data are representative of three independent experiments.
G. da Silva Xavier et al. / Biochemical and Biophysical Research Communications 402 (2010) 252–257 255Indeed, ChREBP is now strongly implicated in the pathogenesis of
fatty liver disease and insulin resistance [8,19] acting to induce lip-
ogenic genes. Very recently, ChREBP was proposed to contribute to
the development of diabetic nephropathy through the induction of
HIF1-a in glomerular mesangial cells [20,21] In the pancreatic b-
cell, ChREBP activation by high glucose results in increases in tri-
glyceride content and a reduction in glucose-stimulated insulin
secretion [9,13]. We show here that, in addition to the direct ef-
fects on L-PK, FAS, Txnip and ARNT promoters previously reported
[9,10,12,13] ChREBP also inhibits the expression of several other
key b-cell genes, namely Pdx-1, MafA, GcK and insulin.
4.2. Regulation of Pdx-1 gene expression by ChREBP
We show ﬁrstly that ChREBP over-expression, both in MIN6 b-
cells and pancreatic islets, inhibits Pdx-1 gene expression at highglucose concentrations, and that ChREBP inactivation, achieved
either by RNA silencing or antibody microinjection into single cells,
increases Pdx-1 expression at low glucose concentrations.
Although ChREBP has been shown to possess intrinsic repressive
capabilities [13,22], we were unable to demonstrate direct binding
of ChREBP in vivo despite scanning the obvious E-boxes, by exten-
sive ChIP assays, at either low or high glucose concentrations (see
Fig. 3). We have considered the possibility that an indirect effect of
changes in intracellular lipid content could explain the effects of
ChREBP on Pdx-1 gene expression, but this would appear to be un-
likely given the absence of effects of either inactivation of endoge-
nous SREBP-1c or over-expression of the activated nuclear
fragment of SREBP-1c on Pdx-1 promoter activity or mRNA levels
(Fig. 1B, D and F), despite well-documented effects of these
manoeuvres on cellular triglyceride content [16,23,24]. One possi-
ble explanation for the apparent inhibitory effects of ChREBP on
Fig. 3. Sequences of the primers and E-boxes in the 2.7 kb Pdx-1 promoter probed by ChIP assay. Positions of 50 and 30 primers are indicated by arrows and those of E-boxes
are highlighted in bold.
Fig. 4. Real-time quantitative PCR analysis of gene expression in mouse islets over-expressing ChREBP. Islets of Langerhans isolated from female CD1 mice aged 12–14 weeks
were transduced with either null-GFP or ChREBP adenoviruses (100 MOI) and cultured in 11 mM glucose RPMI media for 48 h and incubation in RPMI media supplemented
with 3 or 16.7 mM glucose overnight prior to qRT-PCR as described in methods. Data are means ± SEM from three independent experiments done in triplicates, and
normalized to cyclophilin mRNA levels prior to expression as fold change from null infected islets cultured at 3 mM glucose. p < 0.05; p < 0.01; p < 0.001.
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ChREBP normally serves to sequester another activator(s) of Pdx-1
under these conditions. Translocation of ChREBP to the nucleus athigh glucose concentrations, and its activation, either through
covalent modiﬁcation through phosphorylation/dephosphoryla-
tion reactions [25], or through an ill-deﬁned mechanism involving
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bound transcriptional activator, allowing the latter to bind to the
Pdx-1 promoter to stimulate transcription.
It is of note that we were unable here to demonstrate the bind-
ing of USF2 at the 105 E-box of the Pdx-1 promoter. Our ChIP as-
say using both anti-USF and anti-SREBP antibodies has been
validated in this cell type on the FAS promoter [9], making a false
negative unlikely. The discrepancy between data obtained from
in vitro studies and our ChIP assay demonstrates the signiﬁcance
of in vivo (live cell) approaches. Further work will be necessary
to identify the key transcription factor binding to the b-cell speciﬁc
regulatory sequences of the proximal Pdx-1 promoter.
4.3. Regulation of the insulin genes by ChREBP
ChREBP silencing in MIN6 cells resulted in a small, but signiﬁ-
cant, increase in Ins2 gene expression whereas, in primary islets,
ChREBP over-expression only decreased the amount of Ins1 and
Ins2 mRNAs at low glucose, but not at elevated glucose concentra-
tions. One possible explanation may lie in the extremely long half-
life of insulin mRNAs at high glucose concentrations [28], therefore
making a decrease in its transcription rate unnoticeable within the
time course of these experiments.
5. Conclusion
We conclude that ChREBP is a key regulator of adult b-cell phe-
notype, affecting the expression of critical genes. It therefore seems
possible that increases in ChREBP expression, prompted by a dia-
betic milieu, may exacerbate b-cell dysfunction and accelerate b-
cell failure in type 2 diabetes. It would be interesting to know
whether a b-cell speciﬁc ChREBP knockout mouse would be pro-
tected against the development of b-cell failure during the course
of some forms of diabetes.
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